{"denomUnitsSelected":"Participants","description":"Evaluated using Kaplan-Meier methodology.","reportingStatus":"NOT_POSTED","timeFrame":"Time from randomization to first of either disease progression or death from any cause, assessed up to 3 years","title":"PFS in Patients Who Crossover From Single Agent Nivolumab to Dual Agent Treatment Following Progression","type":"OTHER_PRE_SPECIFIED"}